KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

被引：74
|
作者：
Brahmer, J. R. [1 ]
Rodriguez-Abreu, D. [2 ]
Robinson, A. G. [3 ,4 ]
Hui, R. [3 ,4 ]
Csoszi, T. [5 ]
Fulop, A. [6 ]
Gottfried, M. [7 ]
Peled, N. [8 ]
Tafreshi, A. [9 ,10 ]
Cuffe, S. [11 ,12 ]
O'Brien, M. [13 ]
Rao, S. [14 ]
Hotta, K. [15 ]
Leal, T. A. [16 ]
Riess, J. W. [17 ]
Jensen, E. [18 ]
Zhao, B. [18 ]
Pietanza, M. C. [18 ]
Reck, M. [19 ]
机构：
[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA
[2] Hosp Univ Insular Gran Canaria, Med Oncol, Las Palmas Gran Canaria, Spain
[3] Westmead Hosp, Med Oncol, Sydney, NSW, Australia
[4] Univ Sydney, Sydney, NSW, Australia
[5] Jasz Nagykun Szolnok Cty Hosp, Oncol, Szolnok, Hungary
[6] Orszagos Koranyi Pulmonol Intezet, Med Oncol, Budapest, Hungary
[7] Meir Med Ctr, Med Oncol, Kefar Sava, Israel
[8] Soroka Univ Med Ctr, Ctr Canc, Beer Sheva, Israel
[9] Wollongong Private Hosp, Med Oncol, Wollongong, NSW, Australia
[10] Univ Wollongong, Wollongong, NSW, Australia
[11] St James Hosp, Med Oncol, Dublin, Ireland
[12] Canc Trials Ireland, Dublin, Ireland
[13] Royal Marsden Hosp, Med Oncol, Sutton, Surrey, England
[14] MedStar Franklin Sq Hosp, Med Oncol, Baltimore, MD USA
[15] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[16] Univ Wisconsin, Carbone Canc Ctr, Div Hematol & Oncol, Madison, WI USA
[17] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA
[18] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[19] German Ctr Lung Res, Airway Res Ctr North, Lungen Clin, Grosshansdorf, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA51
引用
收藏
页码：S1181 / S1182
页数：2
相关论文
共 50 条
  • [31] IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC
    Spigel, D.
    de Marinis, F.
    Giaccone, G.
    Reinmuth, N.
    Vergnenegre, A.
    Barrios, C. H.
    Morise, M.
    Felip, E.
    Andric, Z. G.
    Geater, S.
    Ozguroglu, M.
    Mocci, S.
    McCleland, M.
    Enquist, I.
    Komatsubara, K. M.
    Deng, Y.
    Kuriki, H.
    Wen, X.
    Jassem, J.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 915 - 915
  • [32] Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
    Sendur, Mehmet Nahit
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Park, Keunchil
    Lee, Dae Ho
    Cicin, Irfan
    Yumuk, Perran Fulden
    Orlandi, Francisco J.
    Leal, Ticiana A.
    Molinier, Olivier
    Soparattanapaisarn, Nopadol
    Langleben, Adrian
    Califano, Raffaele
    Medgyasszay, Balazs
    Hsia, Te-Chun
    Otterson, Gregory Alan
    Xu, Lu
    Burke, Thomas A.
    Samkari, Ayman
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC
    Herbst, Roy
    De Marinis, Filippo
    Giaccone, Giuseppe
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos
    Morise, Masahiro
    Font, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Mocci, Simonetta
    McCleland, Mark
    Enquist, Ida
    Komatsubara, Kim
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    Jassem, Jacek
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A1 - A1
  • [34] THREE-YEAR OUTCOMES WITH FIRST-LINE PEMBROLIZUMAB FOR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) WITH A VERY HIGH PD-L1 TUMOR PROPORTION SCORE (TPS) ≥ 90%
    Ricciuti, Biagio
    Alessi, Joao Victor
    Alden, Stephanie
    Lamberti, Giuseppe
    Vaz, Victor
    Barrichello, Adriana
    Sholl, Lynette
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A336 - A336
  • [35] Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
    Tambo, Yuichi
    Sone, Takashi
    Shibata, Kazuhiko
    Nishi, Kouichi
    Shirasaki, Hiroki
    Yoneda, Taro
    Araya, Tomoyuki
    Kase, Kazumasa
    Nishikawa, Shingo
    Kimura, Hideharu
    Kasahara, Kazuo
    ANNALS OF ONCOLOGY, 2021, 32 : S313 - S313
  • [36] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
    Stares, Mark
    Doyle, Emma
    Chapple, Sally
    Raynes, George
    MacDonald, James
    Barrie, Colin
    Laird, Barry
    MacKean, Melanie
    Philips, Iain
    LUNG CANCER, 2024, 189
  • [37] IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC
    Herbst, R.
    De Marinis, F.
    Giaccone, G.
    Vergnenegre, A.
    Barrios, C.
    Morise, M.
    Felip, E.
    Oprean, C.
    Kim, Y.
    Andric, Z.
    Mocci, S.
    Enquist, I.
    Komatsubara, K.
    Mccleland, M.
    Deng, Y.
    Kuriki, H.
    Villalobos, M.
    Phan, S.
    Spigel, D.
    Jassem, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S224 - S225
  • [38] Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study
    Kawachi, H.
    Tamiya, M.
    Tamiya, A.
    Ishii, S.
    Hirano, K.
    Matsumoto, H.
    Yokoyama, T.
    Ishida, T.
    Ryota, K.
    Fujimoto, D.
    Hosoya, K.
    Suzuki, H.
    Hirashima, T.
    Kanazu, M.
    Sawa, N.
    Uchida, J.
    Morita, M.
    Makio, T.
    Hara, S.
    Kumagai, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
    John, T.
    Ciuleanu, T-E.
    Cobo Dols, M.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E. A.
    Bennouna, J.
    Cheng, Y.
    Felip, E.
    Juan Vidal, O. J.
    Alexandru, A.
    Paz-Ares, L.
    Lu, S.
    Reck, M.
    Hu, N.
    Zhang, X.
    Grootendorst, D. J.
    Eccles, L.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1034 - S1034
  • [40] Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
    Yang, J. C-H.
    Luft, A.
    De la Mora Jimenez, E.
    Lee, J. S.
    Koralewski, P.
    Karadurmus, N.
    Sugawara, S.
    Livi, L.
    Basappa, N. S.
    Quantin, X.
    Dudnik, J.
    Moran Ortiz, D.
    Mekhail, T.
    Okpara, C. E.
    Zimmer, Z.
    Samkari, A.
    Bhagwati, N.
    Csoszi, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1429 - S1430
12345